ziyad m hijazi m d mph fscai facc
play

Ziyad M. Hijazi, M.D., MPH, FSCAI, FACC Professor of Pediatrics - PowerPoint PPT Presentation

Mar 09, 2023 •27 likes •647 views

Vascular Access-Trans-hepatic & Vascular Closure Devices Ziyad M. Hijazi, M.D., MPH, FSCAI, FACC Professor of Pediatrics & Internal Medicine Rush University Medical Center Chicago Monday, December 21, 2009 Vascular

  1. Vascular Access-Trans-hepatic & Vascular Closure Devices Ziyad M. Hijazi, M.D., MPH, FSCAI, FACC Professor of Pediatrics & Internal Medicine Rush University Medical Center Chicago Monday, December 21, 2009

  2. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  3. Vascular Access-Trans-hepatic & Vascular Closure Devices Traditional Venous & arterial Access � 1. Umbilical vein/artery 2. Femoral Veins/arteries 3. Internal Jugular Veins 4. Carotid cutdown 5. Subclavian Veins Monday, December 21, 2009

  4. Vascular Access-Trans-hepatic & Vascular Closure Devices Umbilical vein/Artery Access � 1. Neonatal period-may be up to a week of life 2. Efforts should be made to use this route-spare other access routes for future caths 3. most interventional procedures in neonates can be done using this access. Monday, December 21, 2009

  5. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  6. Vascular Access-Trans-hepatic & Vascular Closure Devices Femoral Vein & Artery � 1. Preferred site for cardiac caths beyond neonatal period 2. Straight access to the right and left heart 3. Femoral veins can accommodate large sheaths Monday, December 21, 2009

  7. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  8. Vascular Access-Trans-hepatic & Vascular Closure Devices Problems Encountered Using Femoral Veins 1. Thrombosis 2. Interruption of the IVC 3. IVC Filters 4. Protection for future catheterization Monday, December 21, 2009

  9. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  10. Vascular Access-Trans-hepatic & Vascular Closure Devices Internal Jugular Vein/Subclavian Vein 1. Suitable alternatives 2. Cumbersome to manipulate catheters/devices from such routes, but are important access sites that catheterizers need to know anatomy well! Monday, December 21, 2009

  11. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  12. Vascular Access-Trans-hepatic & Vascular Closure Devices Carotid Artery 1. cut-down is the preferred method! 2. Usually limit this route to neonatal period-Risk of stroke 3. Neonatal critical AS: this approach has been used for balloon valvuloplasty Monday, December 21, 2009

  13. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  14. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  15. Vascular Access-Trans-hepatic & Vascular Closure Devices Transhepatic Access When other access sites are not available 1.Thrombosis 2. Interruption of the IVC 3. IVC Filters 4. Protection for future catheterization Monday, December 21, 2009

  16. Vascular Access-Trans-hepatic & Vascular Closure Devices Technique 1. Mid axillary line 2. Chiba needle with a stylet � Puncture 1/2 way between diaphragm and liver edge � Orientate the needle horizontal/posterior to 1/2 way from midline � Withdraw stylet; aspirate until blood comes back; inject contrast. 3. 0.018” guide wire 4. Coaxial dilator (4-5Fr) 5. MUOM sheath Monday, December 21, 2009

  17. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  18. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  19. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  20. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  21. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  22. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  23. Vascular Access-Trans-hepatic & Vascular Closure Devices End of Procedure 1. Remove sheath-no coiling 2. Coil closure of tract 3. Gel foam closure of tract Monday, December 21, 2009

  24. Vascular Access-Trans-hepatic & Vascular Closure Devices Coil closure of tract 3mmx4cm coil if sheath 6F or less Coils should be used after sheath was withdrawn and no blood comes back. Multiple coils may be required. Monday, December 21, 2009

  25. Vascular Access-Trans-hepatic & Vascular Closure Devices Gel Foam Monday, December 21, 2009

  26. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  27. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  28. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  29. Vascular Access-Trans-hepatic & Vascular Closure Devices Complications 1. Intraperitoneal hemorrhage 2. Cholangitis Monday, December 21, 2009

  30. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  31. Vascular Access-Trans-hepatic & Vascular Closure Devices Direct LV Puncture Monday, December 21, 2009

  32. Vascular Access-Trans-hepatic & Vascular Closure Devices Indications 1. Double mechanical valves 2. For closure of paravalvar mitral leaks Monday, December 21, 2009

  33. Vascular Access-Trans-hepatic & Vascular Closure Devices Technique 1. CT/TTE to localize the apex of the LV 2. Mark the chest wall 3. Use a 0.021 puncture needle (Micro puncture kit) 4. Place a short sheath 5. Perform study/intervention 6. At end, hold pressure Monday, December 21, 2009

  34. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  35. Vascular Access-Trans-hepatic & Vascular Closure Devices Complications 1. Pericardial effusion 2. Pleural effusion Monday, December 21, 2009

  36. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  37. Vascular Access-Trans-hepatic & Vascular Closure Devices $500 $400 $300 $200 $100 $0 2000 2001 2002 2003 2004 2005 2006 Closure Device Market Medtech Insight. Monday, December 21, 2009

  38. Vascular Access-Trans-hepatic & Vascular Closure Devices The Promise of Vascular closure Devices Patient comfort and convenience Decreased Time to hemostasis Early ambulation Shorter hospital stay Decreased overall procedure-related hospital costs Decreased complication rates Monday, December 21, 2009

  39. Vascular Access-Trans-hepatic & Vascular Closure Devices Categories of closure devices • Anchored plugs • Unanchored plugs • Suture closure • Clip/staple closure • Topical patches • “No footprint” devices • Ultrasound/heat Monday, December 21, 2009

  40. Vascular Access-Trans-hepatic & Vascular Closure Devices Anchored Plugs Active Approximation Angio-Seal Collagen Thrombosing agent Advantages- High success rate, short learning curve, short deployment time Disadvantages-vascular occlusion, potential infection Monday, December 21, 2009

  41. Vascular Access-Trans-hepatic & Vascular Closure Devices Suture and Staple/Clip Devices Active Approximation StarClose Superstitch Perclose AngioLink Monday, December 21, 2009

  42. Vascular Access-Trans-hepatic & Vascular Closure Devices Unanchored Plugs Passive Approximation VasoSeal Duett Thrombosing agent Monday, December 21, 2009

  43. Vascular Access-Trans-hepatic & Vascular Closure Devices New Unanchored Plug Technology Passive Approximation Mynx ExoSeal Vascular Sealants Monday, December 21, 2009

  44. Vascular Access-Trans-hepatic & Vascular Closure Devices No footprint devices Passive approximation Boomerang Catalyst ClosureWire Advantages-No foreign body No thrombosing or sealing agents Monday, December 21, 2009

  45. Vascular Access-Trans-hepatic & Vascular Closure Devices Monday, December 21, 2009

  46. Vascular Access-Trans-hepatic & Vascular Closure Devices Ultrasound/Heat Passive Approximation Therus Epiclose Plus Monday, December 21, 2009

  47. Vascular Access-Trans-hepatic & Vascular Closure Devices Closure Begins with Access Femoral Introducer Sheath and Hemostasis Arstasis device Monday, December 21, 2009

  48. Vascular Access-Trans-hepatic & Vascular Closure Devices Topical Hemostatic Patches Passive Approximation NON-INVASIVE Chito-Seal, Clo-Sur P.A.D., D-Stat, Neptune, Stasys, Syvek Monday, December 21, 2009

  49. Vascular Access-Trans-hepatic & Vascular Closure Devices Which Device to Use? Patient and Vessel specific Heavily anti-coagulated- invasive active approximation Diseased vessel- passive approximation Residual oozing- thrombosing sealing agent or topical hemostatic patch Operator experience/competence Monday, December 21, 2009

  50. Vascular Access-Trans-hepatic & Vascular Closure Devices The Importance of Operator Experience 10 8 6 % 4 2 0 25 75 150 250 350 450 550 650 750 850 930 Patients Balzer et al. CCI 2001; 53: 174 Monday, December 21, 2009

  51. Vascular Access-Trans-hepatic & Vascular Closure Devices The Importance of Operator Experience 10 8 6 % 4 2 0 25 75 150 250 350 450 550 650 750 850 930 Patients Balzer et al. CCI 2001; 53: 174 Monday, December 21, 2009

  52. Vascular Access-Trans-hepatic & Vascular Closure Devices Moral of the Learning Curve Monday, December 21, 2009

Recommend

Submassive PE: When do you stop therapy? Andrew J. P. Klein, MD, FACC, FSCAI Interventional

Submassive PE: When do you stop therapy? Andrew J. P. Klein, MD, FACC, FSCAI Interventional

Massive and Submassive PE: When do you stop therapy? Andrew J. P. Klein, MD, FACC, FSCAI Interventional Cardiology Vascular and Endovascular Medicine Piedmont Heart Institute Atlanta, GA Disclosures: I have nothing to disclose.

376 views • 27 slides
Dr. Nikolas Wanahita MD, MHA, FACC, FSCAI Internist, General and Interventional Cardiologist

Dr. Nikolas Wanahita MD, MHA, FACC, FSCAI Internist, General and Interventional Cardiologist

Dr. Nikolas Wanahita MD, MHA, FACC, FSCAI Internist, General and Interventional Cardiologist Medical Director Gramercy Heart and Vascular Centre Mount Elizabeth Novena Hospital Jantung Sehat & Covid-19 1. Covid 19 Statistics Cases

692 views • 36 slides
Demystifying IVUS Interpretation Nicolas W Shammas, MD, MS, EJD, FACC, CC, FSCAI CAI, FSVM

Demystifying IVUS Interpretation Nicolas W Shammas, MD, MS, EJD, FACC, CC, FSCAI CAI, FSVM

Demystifying IVUS Interpretation Nicolas W Shammas, MD, MS, EJD, FACC, CC, FSCAI CAI, FSVM President and Re Research Director, Midwe west Cardiovascular Re Research Foundation Interventional Cardiologi gist; Coronary and Peripheral

714 views • 60 slides
Sponsors Discussants Milan Gupta Narendra Singh Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC

Sponsors Discussants Milan Gupta Narendra Singh Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC

Sponsors Discussants Milan Gupta Narendra Singh Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC MD, FRCPC, FCCS, FACC, FAHA MD, FRCPC, FCCS, FACC, FAHA Associate Clinical Professor Director, Clinical Research, Atlanta Heart Executive

1.08k views • 87 slides
Discussants Milan Gupta Narendra Singh Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC MD,

Discussants Milan Gupta Narendra Singh Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC MD,

Discussants Milan Gupta Narendra Singh Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC MD, FRCPC, FCCS, FACC, FAHA MD, FRCPC, FCCS, FACC, FAHA Associate Clinical Professor Director, Clinical Research, Atlanta Heart Executive Director,

968 views • 85 slides
Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical

Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical

Final five-year clinical outcomes in the EVOLVE trial: A randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian T. Meredith AM MBBS, PhD, FRACP, FCSANZ, FACC, FSCAI, FAPSIC MonashHeart, Monash Medical Centre

542 views • 15 slides
Debulking Below the Knee: Devices & Techniques Jihad A. Mustapha, MD, FSCAI, FACC Advanced

Debulking Below the Knee: Devices & Techniques Jihad A. Mustapha, MD, FSCAI, FACC Advanced

Debulking Below the Knee: Devices & Techniques Jihad A. Mustapha, MD, FSCAI, FACC Advanced Cardiac & Vascular Centers for Amputation Prevention Grand Rapids, MI Disclosures Bard Peripheral Vascular Consultant Boston Scientific

435 views • 27 slides
Hasan Abdallah, MD,FAAP,FACC,FSCAI POTS is a symptom complex rather than a disease entity

Hasan Abdallah, MD,FAAP,FACC,FSCAI POTS is a symptom complex rather than a disease entity

Hasan Abdallah, MD,FAAP,FACC,FSCAI POTS is a symptom complex rather than a disease entity itself, with underlying heterogeneous pathophysiologies , such as: Neuropathic Mast Cell activation Autoimmune Index Case 16 years old

361 views • 34 slides
CLI Case Study Jihad A. Mustapha, MD, FACC, FSCAI Advanced Cardiac & Vascular Centers for

CLI Case Study Jihad A. Mustapha, MD, FACC, FSCAI Advanced Cardiac & Vascular Centers for

CLI Case Study Jihad A. Mustapha, MD, FACC, FSCAI Advanced Cardiac & Vascular Centers for Amputation Prevention Grand Rapids, MI, USA Clinical Associate Professor of Medicine Michigan State University College of Human Medicine E. Lansing,

513 views • 20 slides
Distal foot reconstruction: When and How Ramzan M. Zakir, MD, RPVI, FACC, FSCAI Clinical

Distal foot reconstruction: When and How Ramzan M. Zakir, MD, RPVI, FACC, FSCAI Clinical

Distal foot reconstruction: When and How Ramzan M. Zakir, MD, RPVI, FACC, FSCAI Clinical Associate Professor of Medicine Rutgers-Robert Wood Johnson Medical School Director of Complex Cardiovascular Interventions & Research Robert Wood

973 views • 30 slides
Case 1: Perfusion Challenges Sahil A. Parikh, MD, FACC, FSCAI Associate Professor of Medicine

Case 1: Perfusion Challenges Sahil A. Parikh, MD, FACC, FSCAI Associate Professor of Medicine

SCAI 2019 May 22, 2019 Case 1: Perfusion Challenges Sahil A. Parikh, MD, FACC, FSCAI Associate Professor of Medicine Director, Endovascular Services Center for Interventional Vascular Therapy New York-Presbyterian Hospital Columbia

710 views • 24 slides
Are Drug Eluting Stents the Future of SFA Treatment? Sahil A. Parikh, MD, FACC, FSCAI Associate

Are Drug Eluting Stents the Future of SFA Treatment? Sahil A. Parikh, MD, FACC, FSCAI Associate

SCAI 2019 May 22, 2019 Are Drug Eluting Stents the Future of SFA Treatment? Sahil A. Parikh, MD, FACC, FSCAI Associate Professor of Medicine Director, Endovascular Services Center for Interventional Vascular Therapy New York-Presbyterian

310 views • 29 slides
to Consider. Case Examples . Anand Prasad, MD, FACC, FSCAI, RPVI Associate Professor of Medicine

to Consider. Case Examples . Anand Prasad, MD, FACC, FSCAI, RPVI Associate Professor of Medicine

Heavily Calcified SFA Lesions: Treatment Strategies to Consider. Case Examples . Anand Prasad, MD, FACC, FSCAI, RPVI Associate Professor of Medicine at UT Health San Antonio Director Cardiac Catheterization Laboratory University Health System

667 views • 20 slides
Updated Results and Implications of the Lipid Rich Plaque Study Ron Waksman, MD, FACC, FSCAI,FESC

Updated Results and Implications of the Lipid Rich Plaque Study Ron Waksman, MD, FACC, FSCAI,FESC

Updated Results and Implications of the Lipid Rich Plaque Study Ron Waksman, MD, FACC, FSCAI,FESC Professor of Medicine Georgetown University Associate Director of Cardiology Director of Cardiovascular Research and Education MedStar Washington

509 views • 29 slides
Stent Regrets, Ive Had a Few! Faisal Latif MD, FSCAI, FACC Director Cardiac Catheterization

Stent Regrets, Ive Had a Few! Faisal Latif MD, FSCAI, FACC Director Cardiac Catheterization

Stent Regrets, Ive Had a Few! Faisal Latif MD, FSCAI, FACC Director Cardiac Catheterization Lab, VAMC Associate Professor of Medicine Governor, Oklahoma Chapter of ACC Associate Program Director, CV Fellowship University of Oklahoma

542 views • 26 slides
How to treat diabetes in China Shao-Liang Chen, MD, FSCAI, FACC Nanjing First Hospital Nanjing

How to treat diabetes in China Shao-Liang Chen, MD, FSCAI, FACC Nanjing First Hospital Nanjing

How to treat diabetes in China Shao-Liang Chen, MD, FSCAI, FACC Nanjing First Hospital Nanjing Medical University, China E-mail: chmengx@126.com Current status of Diabetes in China Year Country 2000 2030 Ranking People with

271 views • 26 slides
cardiogenic shock team Sandeep Nathan, MD, MSc, FACC, FSCAI Associate Professor of Medicine

cardiogenic shock team Sandeep Nathan, MD, MSc, FACC, FSCAI Associate Professor of Medicine

Key elements of a cardiogenic shock team Sandeep Nathan, MD, MSc, FACC, FSCAI Associate Professor of Medicine Medical Director, Cardiac Intensive Care Unit Director, Interventional Cardiology Fellowship Program Co-Director, Cardiac

730 views • 27 slides
Alternatives to CDT: Half-dose Thrombolytics and Mechanical Thrombectomy Thomas Tu, MD FSCAI,

Alternatives to CDT: Half-dose Thrombolytics and Mechanical Thrombectomy Thomas Tu, MD FSCAI,

Alternatives to CDT: Half-dose Thrombolytics and Mechanical Thrombectomy Thomas Tu, MD FSCAI, FACC The Dawn of A New Era of PE Therapy A Sunrise Pulmonary Embolism Symposium May 22, 2019 Disclosures None currently As of July 1, 2019,

759 views • 36 slides
Stent For Life, Egypt A Success Story Hany Ragy MD, FSCAI NHI, Cairo, Egypt @hragy Stent For

Stent For Life, Egypt A Success Story Hany Ragy MD, FSCAI NHI, Cairo, Egypt @hragy Stent For

Stent For Life, Egypt A Success Story Hany Ragy MD, FSCAI NHI, Cairo, Egypt @hragy Stent For Life Initiative in Egypt Professor Mohamed Sobhy , MD, FACC, FESC Professor of Cardiology Department, Alexandria University - Egypt Past President

429 views • 30 slides
Charles L. Laham, MD, FSCAI, Michael S Chandra, MD, Richard Kettelkamp, MD, PhD, FSCAI, Nicolas W

Charles L. Laham, MD, FSCAI, Michael S Chandra, MD, Richard Kettelkamp, MD, PhD, FSCAI, Nicolas W

OUTSIDE START Cilostazol Bridge Study: 8 year experience with Outpatient Cilostazol Bridging in High Stent Thrombosis Risk Paclitaxel Drug Eluting Stents in Patients having Surgery during the Proven at risk Period Charles L. Laham, MD, FSCAI,

301 views • 15 slides
Cardiogenic Shock Algorithm and Case Presentation SCAI SHOCK - 2018 Jaya Mallidi, MD, MHS, FACC,

Cardiogenic Shock Algorithm and Case Presentation SCAI SHOCK - 2018 Jaya Mallidi, MD, MHS, FACC,

Cardiogenic Shock Algorithm and Case Presentation SCAI SHOCK - 2018 Jaya Mallidi, MD, MHS, FACC, FSCAI Interventional Cardiologist, St Joseph Memorial Hospital & Sutter Regional Hospital, Santa Rosa, CA Disclosures No disclosures

1.53k views • 35 slides
Process Improvement in Governmental Agencies Toward CMMI Certification Ziyad Alshaikh, Mansour

Process Improvement in Governmental Agencies Toward CMMI Certification Ziyad Alshaikh, Mansour

Process Improvement in Governmental Agencies Toward CMMI Certification Ziyad Alshaikh, Mansour Alsaleh, Abdulrahman Alarifi Computer Research Institute King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia Mohammad

422 views • 18 slides
16% http://www.diabetes.org OECD 2015 We are not only sicker , but we are also exporting our

16% http://www.diabetes.org OECD 2015 We are not only sicker , but we are also exporting our

10/25/2018 Obesity rates by country Benefits of Plant-Based Nutrition the inconvenient truth Payam Fallahi, MD, FACC, FSCAI Interventional Cardiology, Hagerstown Heart Certificate in Plant-Based Nutrition Center for Nutrition Studies,

438 views • 10 slides
solutions in Formal? Ziyad Hanna VP Research and Chief Architect Jasper Design Automation Nov

solutions in Formal? Ziyad Hanna VP Research and Chief Architect Jasper Design Automation Nov

What will be the next breakthrough solutions in Formal? Ziyad Hanna VP Research and Chief Architect Jasper Design Automation Nov 2009 Customers Most Pressing Problems Understand & manage design complexity Reduce verification and

228 views • 5 slides

More recommend